{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Myeloma&page=40", "query": { "condition": "Multiple Myeloma", "page": 40 }, "page_size": 10 }, "pagination": { "page": 40, "page_size": 10, "total_count": 471, "total_pages": 48, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Myeloma&page=41&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Myeloma&page=39&page_size=10" }, "source": "local", "last_synced_at": "2026-10-28T02:19:34.300Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04756726", "title": "Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, Non-Hodgkin's", "Multiple Myeloma" ], "interventions": [ { "name": "Dexamethasone Oral", "type": "DRUG" }, { "name": "cemsidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "C4 Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 224, "start_date": "2021-04-27", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-03-25", "last_synced_at": "2026-09-21T00:04:47.653Z", "location_count": 13, "location_summary": "Phoenix, Arizona • San Francisco, California • Denver, Colorado + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04756726" }, { "nct_id": "NCT04268498", "title": "A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Autologous Stem Cell Transplant (ASCT)", "type": "BIOLOGICAL" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Montelukast", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 310, "start_date": "2020-02-11", "completion_date": "2027-02-01", "has_results": false, "last_update_posted_date": "2026-03-24", "last_synced_at": "2026-10-08T00:03:51.893Z", "location_count": 7, "location_summary": "Miami, Florida • Tampa, Florida • Buffalo, New York + 4 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Stony Brook", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04268498" }, { "nct_id": "NCT02773030", "title": "A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Bortezomib (BTZ)", "type": "DRUG" }, { "name": "CC-220", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Daratumumab - 16mg/kg", "type": "DRUG" }, { "name": "Daratumumab- 1800mg", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 466, "start_date": "2016-10-14", "completion_date": "2028-07-28", "has_results": true, "last_update_posted_date": "2026-03-20", "last_synced_at": "2026-10-28T02:19:34.300Z", "location_count": 58, "location_summary": "Scottsdale, Arizona • Little Rock, Arkansas • Atlanta, Georgia + 24 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02773030" }, { "nct_id": "NCT06357975", "title": "Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Lymphoma", "Advanced Malignant Solid Neoplasm", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Crizotinib", "type": "DRUG" }, { "name": "Radiologic Examination", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2016-07-29", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-03-19", "last_synced_at": "2026-10-15T03:56:43.893Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06357975" }, { "nct_id": "NCT02952508", "title": "Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Central Nervous System Lymphoma", "Chronic Lymphocytic Leukemia", "Diffuse Large B Cell Lymphoma", "Lymphoplasmacytic Lymphoma", "Mantle Cell Lymphoma", "Marginal Zone Lymphoma", "Multiple Myeloma", "Small Lymphocytic Lymphoma", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "Iopofosine I 131 fractionated dose", "type": "DRUG" }, { "name": "Iopofosine I 131 multiple dose", "type": "DRUG" }, { "name": "Iopofosine I 131 single dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cellectar Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2017-07-26", "completion_date": "2027-12-22", "has_results": false, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-10-11T03:04:40.384Z", "location_count": 29, "location_summary": "Los Angeles, California • Redlands, California • Washington D.C., District of Columbia + 25 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Redlands", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02952508" }, { "nct_id": "NCT05257083", "title": "A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Cilta-cel", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stichting European Myeloma Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 759, "start_date": "2023-10-10", "completion_date": "2040-08", "has_results": false, "last_update_posted_date": "2026-03-17", "last_synced_at": "2026-10-14T18:14:17.080Z", "location_count": 27, "location_summary": "Little Rock, Arkansas • Duarte, California • San Diego, California + 21 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05257083" }, { "nct_id": "NCT05767359", "title": "CAR- PRISM (PRecision Intervention Smoldering Myeloma)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma", "Smoldering Multiple Myeloma" ], "interventions": [ { "name": "Ciltacabtagene Autoleucel", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2023-04-19", "completion_date": "2040-01-15", "has_results": false, "last_update_posted_date": "2026-03-12", "last_synced_at": "2026-10-16T08:04:11.126Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05767359" }, { "nct_id": "NCT06045806", "title": "A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "idecabtagene vicleucel", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 79, "start_date": "2023-10-16", "completion_date": "2029-11-20", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-10-14T18:19:35.766Z", "location_count": 20, "location_summary": "Los Angeles, California • Orange, California • Sacramento, California + 14 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06045806" }, { "nct_id": "NCT04094961", "title": "Ixazomib + Pomalidomide + Dexamethasone In MM", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma", "Multiple Myeloma in Relapse" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Ixazomib", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Omar Nadeem, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2019-09-18", "completion_date": "2027-01-01", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-10-16T01:13:45.268Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04094961" }, { "nct_id": "NCT03741127", "title": "Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Rimiducid may be administered as indicated", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Poseida Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2018-10-29", "completion_date": "2032-11", "has_results": false, "last_update_posted_date": "2026-03-04", "last_synced_at": "2026-07-29T09:31:08.917Z", "location_count": 13, "location_summary": "Davis, California • San Diego, California • San Francisco, California + 8 more", "locations": [ { "city": "Davis", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03741127" } ] }